Amarantus BioSciences has announced positive behavioural efficacy data of MANF when compared to GDNF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease.
In the studies 6-OHDA was primarily injected into the striatum on one side of each rat’s brain, enabling dopaminergic terminals to retract from the striatum towards the substantia nigra thereby creating Parkinson’s-like behavioural symptoms.
Two weeks after the administration of the 6-OHDA, MANF and GDNF at the optimal dosing level of 10 micrograms were administered into the substantia nigra of separate groups of rats.
The studies observed that four weeks following MANF treatment, behavioural deficits were reduced by 43% and six weeks following MANF treatment, behavioural deficits were reduced by 53%.
Four weeks following GDNF treatment, behavioural deficits were reduced by 16%, and six weeks following GDNF treatment, behavioural deficits increased by 20%.
Amarantus president and CEO Gerald Commissiong said, "The data we now have validates the approach we have been taking over the last several years, and we believe that it will allow us to attract the interest of investment firms and potential partners who will be able to now characterize the substantial opportunity our technology represents."